(Q34722604)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12099972%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

review article

1 reference

title

PPARgamma and the thiazolidinediones: molecular basis for a treatment of 'Syndrome X'? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12099972%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12099972%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

author name string

C Sewter

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12099972%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

publication date

1 July 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12099972%20AND%20SRC:MED&resulttype=core&format=json

Diabetes, Obesity and Metabolism

10 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12099972%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12099972%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12099972%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

page(s)

239-248

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12099972%20AND%20SRC:MED&resulttype=core&format=json

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

10 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

The organization, promoter analysis, and expression of the human PPARgamma gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

cDNA cloning and characterization of the transcriptional activities of the hamster peroxisome proliferator-activated receptor haPPAR gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Expression and cDNA cloning of porcine peroxisome proliferator-activated receptor gamma (PPARgamma).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

The nuclear receptor ligand-binding domain: structure and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Molecular recognition of fatty acids by peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more....

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Exercise and thiazolidinedione therapy normalize insulin action in the obese Zucker fatty rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Thiazolidinediones in the treatment of insulin resistance and type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR gamma and C/EBP alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

The hormone resistin links obesity to diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Thiazolidinediones and insulin resistance: peroxisome proliferatoractivated receptor gamma activation stimulates expression of the CAP gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Thiazolidinediones (PPARgamma agonists) but not PPARalpha agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Troglitazone action is independent of adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

In vitro studies on the action of CS-045, a new antidiabetic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

PPAR gamma is required for placental, cardiac, and adipose tissue development

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Obesity associated with a mutation in a genetic regulator of adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Low density lipoprotein oxidation and its pathobiological significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

The role of PPAR-gamma in macrophage differentiation and cholesterol uptake.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Regulation of FAT/CD36 gene expression: further evidence in support of a role of the protein in fatty acid binding/transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Antihypertensive effects of CS-045 treatment in obese Zucker rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Effects of ciglitazone on blood pressure and intracellular calcium metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Troglitazone lowers blood pressure and enhances insulin sensitivity in Watanabe heritable hyperlipidemic rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

The PPARs: from orphan receptors to drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Hypertension and insulin resistance: role of peroxisome proliferator-activated receptor gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Terminal differentiation of human breast cancer through PPAR gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Loss-of-Function Mutations in PPARγ Associated with Human Colon Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00187.X

Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension

21 January 2018

1 reference

COCI

https://opencitations.net/index/coci/api/v1/citations/10.1038/47254

10.1046/J.1463-1326.2002.00187.X

15 July 2023

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12099972%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference